This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
What's in the Cards for Novavax (NVAX) This Earnings Season?
by Zacks Equity Research
Investors are looking forward to Novavax's (NVAX) updates on its pipeline candidates when it reports third-quarter 2018 results.
Neurocrine (NBIX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investors are expected to focus on Neurocrine's (NBiX) updates on its pipeline candidates when it reports third-quarter results.
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is a Beat in Store for CRISPR (CRSP) This Earnings Season?
by Zacks Equity Research
We expect CRISPR (CRSP) to provide updates on its pipeline candidates in the third quarter of 2018.
What's in the Cards for AbbVie (ABBV) This Earnings Season?
by Zacks Equity Research
Impressive sales of AbbVie's (ABBV) key drugs, Humira, Imbruvica and Mavyret are expected to drive third-quarter sales.
Molina Healthcare's (MOH) Q3 Earnings: Is a Beat in Store?
by Zacks Equity Research
Molina Healthcare (MOH) is likely to perform well in the third quarter on the back of a solid Medicaid business and its operational excellence.
The Zacks Analyst Blog Highlights: Allergan, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and AMAG Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Allergan, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and AMAG Pharmaceuticals
5 Drug/Biotech Stocks Likely to Beat Estimates in Q3 Earnings
by Zacks Equity Research
We take a look at a few stocks that might deliver an earnings beat when they report next week.
Is a Beat in Store for Zoetis (ZTS) This Earnings Season?
by Zacks Equity Research
Zoetis' (ZTS) diversified product portfolio, global footprint and productive R&D should help drive both top-and bottom-line growth in the third quarter of 2018.
Alexion (ALXN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Let's look at the factors that will impact Alexion's (ALXN) third -quarter 2018 earnings scheduled to release on Oct 24.
Alnylam to Pursue Full Approval & Rolling NDA for Givosiran
by Zacks Equity Research
Alnylam (ALNY) plans to pursue a full approval of givosiran and submit rolling new drug application (NDA) for the same.
J&J Inks Deal With Arrowhead for Promising Liver Candidate
by Zacks Equity Research
Johnson & Johnson (JNJ) signs a licensing pact with Arrowhead to develop the latter's RNAi therapy candidate, ARO-HBV, for treating chronic hepatitis B viral infection. The deal is worth $3.7 billion.
Alnylam Files Clinical Trial Application for ALN-AAT02 in UK
by Zacks Equity Research
Alnylam Pharmaceuticals (ALNY) submits a Clinical Trial Authorization application in the U.K. to start a phase I/II study on its early stage candidate, ALN-AAT02, for treating alpha-1 liver disease.
Medicines Company to Continue Inclisiran Studies as Planned
by Zacks Equity Research
The Medicines Company (MDCO) gets Independent Data Monitoring Committee's recommendation to continue late-stage inclisiran studies as planned and designed.
Here's Why Alynlam Pharmaceuticals is Hogging the Limelight
by Zacks Equity Research
Alnylam (ALNY) files an NDA for Onpattro in Japan and releases positive interim results for givosiran.
Alnylam's Shares Up as Onpattro Gets FDA and EU Approvals
by Zacks Equity Research
Shares of Alnylam (ALNY) increase due to the FDA and European approval for Onpattro.
Sanofi's Blood Disorder Drug Cablivi Gets Approval in Europe
by Zacks Equity Research
Sanofi's (SNY) Cablivi receives approval for the treatment of acquired thrombotic thrombocytopenic purpura, a rare blood clotting disorder.
Alnylam Gets European Nod for First-Ever RNAi Therapeutic
by Zacks Equity Research
Alnylam's (ALNY) Onpattro, the first ever RNA interference (RNAi) therapeutic, has been granted marketing authorization by the European Commission.
Pfizer's Tafamidis Fails to Impress in Cardiomyopathy Study
by Zacks Equity Research
Pfizer's (PFE) tafamidis significantly reduces rate of mortality and cardiovascular-related hospitalization in patients with transthyretin amyloid cardiomyopathy. However, it fails to impress investors. Stock dips.
Alnylam Completes Enrollment in Phase III Givosiran Study
by Zacks Equity Research
Alnylam Pharmaceuticals (ALNY) completes enrollment in the phase III ENVISION study ahead of schedule of its pipeline candidate, givosiran.
Biotech Stock Roundup: Label Expansion of Regeneron's Eylea, Vertex's Kalydeco
by Zacks Equity Research
The biotech sector witnesses a pretty low key week with a handful of regulatory updates. Regeneron secures an FDA approval for the label expansion of its key drug Eylea.
Alnylam (ALNY) Gets FDA Nod for First-Ever RNAi Therapeutic
by Zacks Equity Research
Alnylam (ALNY) receives FDA approval for Onpattro to treat polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.
Alnylam's (ALNY) Q2 Loss Wider Than Expected, Sales Beat
by Zacks Equity Research
Alnylam (ALNY) posted wider-than-expected loss in the second quarter of 2018 and received a positive opinion from the CHMP for the marketing authorization of patisiran.
Medicines Company (MDCO) Q2 Loss Narrows, Revenues Tank Y/Y
by Zacks Equity Research
The Medicines Company (MDCO) beats earnings estimates while missing the same for revenues in the second quarter.
Alnylam Pharmaceuticals (ALNY) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alnylam (ALNY) delivered earnings and revenue surprises of -4.55% and 50.03%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?